长期治疗瓦尔德纳菲尔的可能视网膜毒性
Klaudia Szabó1, Bulcsú Dékány2, Anna Énzsöly3
1Institute of Education and Psychology at Szombathely, Faculty of Education and Psychology, ELTE Eötvös Loránd University, Szombathely, Hungary; Department of Anatomy, Histology and Embryology, Semmelweis University, Budapest, Hungary.
Experimental eye research
|April 14, 2024
概括
长期使用瓦德纳菲尔可能会损害视网膜,甚至在非糖尿病患者中引起毒性. 这种基化酶 (PDE) 抑制剂表现出混合作用,影响杆细胞和视网膜厚度.
科学领域:
- 眼科医生 眼科 眼科
- 药理学 药理学是指药理学的学科.
- 糖尿病学 糖尿病学
背景情况:
- 固酶 (PDE) 抑制剂,如瓦尔德纳菲尔,通过增加循环诺单酸盐 (cGMP) 来治疗勃起功能障碍.
- 这些抑制剂不是PDE5特异性的,可以影响视网膜异型,可能导致由于持续的cGMP升高而导致光受体毒性.
- 在糖尿病等疾病中,PDE抑制剂的心脏保护作用在长期使用时被注意到.
研究的目的:
- 为了研究长期治疗瓦尔德纳菲尔的潜在视网膜毒性.
- 在2型糖尿病的临床前模型中评估瓦德纳菲尔对视网膜的影响.
主要方法:
- 从瘦肉和糖尿病的糖糖尿病脂肪大鼠的视网膜的组织学检查.
- 在一小组动物中进行了六个月的瓦德纳菲尔治疗.
- 视网膜结构和细胞变化的评估.
主要成果:
- 瓦德纳菲尔治疗显示出混合的结果,缓解了一些杆外部段变性,但减少了杆数量并改变了互光受体矩阵.
- 视网膜厚度和外核层细胞数量在对照组和糖尿病组都减少.
- 观察到穆勒细胞激活和化,而瓦尔德纳菲尔并没有改善糖尿病大鼠的化.
结论:
- 长期使用瓦德纳菲尔可能会导致视网膜毒性,这与糖尿病无关.
- 这些发现引发了长时间连续使用vardenafil的视网膜安全性的担忧.
- 在批准PDE抑制剂用于新适应症时,必须考虑潜在的不良视网膜影响.
相关概念视频
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
150
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
150
01:11Renal Failure: Dose Adjustments
88
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
88
01:20Desensitization and Tachyphylaxis
1.7K
Tachyphylaxis is described as a rapid decrease in response to a drug after repeated or continuous administration of the same drug dose. It is a phenomenon where the body becomes less responsive to a particular substance or intervention over time, requiring higher doses or stronger interventions to achieve the same effect. It results from adaptive changes in the body's receptors, signaling pathways, or physiological processes that occur in response to prolonged exposure to a stimulus.
1.7K
01:19Pharmacovigilance
830
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
830